A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation

Author(s):Show less -

Bacelar Marques, Igor Denizarde ^[1] ; Lima Nepomuceno Araujo, Maria Julia Correia ^{[2, 1]} ; Graciolli, Fabiana Giorgetti ^[2] ; dos Reis, Luciene Machado ^[2] ; Pereira, Rosa Maria R. ^[3] ; Alvarenga, Jackeline C. ^[3] ; Custodio, Melani Ribeiro ^{[2, 1]} ; Jorgetti, Vanda ^[2] ; Elias, Rosilene Motta ^[2] ; Affonso Moyses, Rosa Maria ^[2] ; David-Neto, Elias ^{[2, 1]}

Affiliation

^[1] Univ Sao Paulo, Fac Med, Hosp Clin, Urol Div, Renal Transplant Serv, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Hosp Clin, Nephrol Div, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Hosp Clin, Rheumatol Div, Sao Paulo - Brazil

• Document type: Journal article
• Source: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY; v. 30, n. 2, p. 355-365, FEB 2019.
• Web of Science Citations: 7

Abstract

Background Bone and mineral disorders commonly affect kidney transplant (KTx) recipients and have been associated with a high risk of fracture. Bisphosphonates may prevent or treat bone loss in such patients, but there is concern that these drugs might induce adynamic bone disease (ABD). Methods In an open label, randomized trial to assess the safety and efficacy of zoledronate for preventing bone loss in the first year after kidney transplant, we randomized 34 patients before transplant to receive zoledronate or no treatment. We used dual-energy x-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT), and bone biopsies to evaluate changes in bone in the 32 evaluable participants between the time of KTx and 12 months post-transplant. Results Both groups of patients experienced decreased bone turnover after KTx, but zoledronate itself did not affect this outcome. Unlike previous studies, DXA showed no post-transplant bone loss in either group; we instead observed an increase of bone mineral density in both lumbar spine and total hip sites, with a significant positive effect of zoledronate. However, bone biopsies showed post-transplant impairment of trabecular connectivity (and no benefit from zoledronate); HR-pQCT detected trabecular bone loss at the peripheral skeleton, which zoledronate partially attenuated. Conclusions Current immunosuppressive regimens do not contribute to post-transplant central skeleton trabecular bone loss, and zoledronate does not induce ABD. Because fractures in transplant recipients are most commonly peripheral fractures, clinicians should consider bisphosphonate use in patients at high fracture risk who have evidence of significantly low bone mass at these sites at the time of KTx. (AU)

• FAPESP's process: 11/22962-3 - A prospective and randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation
• Grantee: Elias David-Neto
• Support Opportunities: Regular Research Grants